Drugs / Zanolimumab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT01160445 | Jun 2010 → Jan 2012 | kidney cancer, metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00893516 | May 2007 → Oct 2008 | T-cell non-Hodgkin lymphoma | Emergent BioSolutions | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00071084 | May 2003 → Jun 2004 | primary cutaneous T-cell lymphoma | Genmab | Completed | No outcome recorded |
| Phase 2 | NCT00071071 | Apr 2003 → May 2004 | primary cutaneous T-cell lymphoma | Genmab | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00877656 | Aug 2005 → Jan 2006 | T-cell non-Hodgkin lymphoma | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 2/3 | NCT00042406 | Mar 2002 → Mar 2003 | rheumatoid arthritis | Genmab | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00127881 | Jul 2005 → Feb 2014 | Sezary syndrome, mycosis fungoides | Emergent Product Development Seattle LLC | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zanolimumab | “A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With...” NCT00893516 ↗ |
| Known as | HuMax-CD4 | “HuMax-CD4 (zanolimumab)” NCT00127881 ↗ |
| Known as | MDX-016 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108063 ↗ |
| Action | Deplete | “Zanolimumab is an antibody that works by destroying CD4 cells in the blood.” NCT01160445 ↗ |
| Modality | Monoclonal antibody | “Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4)” NCT00042406 ↗ |
| Route | Subcutaneous | “administered as a subcutaneous infusion” NCT00042406 ↗ |
| Target | CD4 | “Anti-CD4 Receptor Human Monoclonal Antibody” NCT00042406 ↗ |